Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics to Participate at Upcoming Investor Conferences
04:05pm, Tuesday, 04'th Nov 2025
SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Prediction: The Next Eli Lilly Might Already Be Trading Under $50
04:45am, Monday, 03'rd Nov 2025
Viking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide. The mid-cap biotech is exploring options for a potential quadruple agonist therapy.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of “Moderate Buy” by Brokerages
01:47am, Monday, 03'rd Nov 2025
Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seventeen brokerages that are presently covering the firm, Marketbeat repo
Should You Buy Viking Therapeutics Before Nov. 5?
09:20am, Sunday, 02'nd Nov 2025
Viking Therapeutics aims to enter one of today's biggest healthcare growth areas: the weight loss drug market. The company is evaluating an injectable candidate in phase 3 studies and an oral candidat
AlphaQuest LLC Sells 2,913 Shares of Viking Therapeutics, Inc. $VKTX
03:59am, Sunday, 02'nd Nov 2025
AlphaQuest LLC cut its holdings in Viking Therapeutics, Inc. (NASDAQ: VKTX) by 24.8% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 8,840 shares of the
3 Promising Growth Stocks That Are Down Around 60% From Their Highs
04:55am, Friday, 31'st Oct 2025
Viking Therapeutics, Cava Group, and Figma are three stocks that have been struggling in recent months. These businesses possess some exciting growth potential, which could make them ideal long-term i
3 Explosive Stocks With High Short Interest
09:40am, Thursday, 30'th Oct 2025
The image featured for this article is © Ground Picture / Shutterstock.com
Charles Rowland, Jr. Sells 60,000 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock
05:26am, Thursday, 30'th Oct 2025
Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) Director Charles Rowland, Jr. sold 60,000 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average pric
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
04:05pm, Wednesday, 29'th Oct 2025
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific S
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Monday, 27'th Oct 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Viking Therapeutics: High Risk, High Reward Play
09:06am, Monday, 27'th Oct 2025
Viking Therapeutics Inc. NASDAQ: VKTX stock is soaring after the company delivered its third-quarter earnings report. The clinical-stage biopharmaceutical company is not profitable and is not generati
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
03:56pm, Thursday, 23'rd Oct 2025
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
Here's Why This Obesity Drug Company's Share Price Soared Today
02:36pm, Thursday, 23'rd Oct 2025
The company's lead drug candidate is in a phase 3 trial, and enrollment is progressing well. The drug is also being tested in oral formulation, and there's plenty of value in Viking's pipeline.
Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)
10:42am, Thursday, 23'rd Oct 2025
Viking Therapeutics, Inc. remains a Buy as VK2735 is arguably the leading GLP-1 obesity drug candidate outside of Eli Lilly and Novo Nordisk's pipelines. VKTX's pivotal VANQUISH Phase 3 injectable stu
Viking Therapeutics: The Prime Target In The Obesity Gold Rush
10:05am, Thursday, 23'rd Oct 2025
Viking Therapeutics, Inc. is a clinical-stage biotech focused on metabolic and endocrine therapies, highlighted by its promising VK2735 obesity drug. VKTX's pipeline includes late-stage GLP-1/GIP agon
